血清及癌组织VEGF及其受体在结肠癌患者中的变化观察

Observation on the Change of Serum and Cancer Tissue VEGF and Its Receptors of Patients with Colon Cancer

目的:观察血清及癌组织VEGF(VEGF-A、VEGF-C)及其受体(VEGFR-3)在结肠癌患者中的变化。方法:选取2013年3月-2018年5月本院诊治的结肠癌患者100例为观察组,同期结肠良性病变患者100例为对照组。检测与比较两组血清VEGF及其受体水平、组织VEGF及其受体阳性率,并比较其在观察组不同分期与分化程度中的差异。结果:观察组血清VEGF及其受体水平、组织VEGF及其受体阳性率均高于对照组,且不同分期与分化程度结肠癌患者间血清VEGF及其受体水平、组织VEGF及其受体阳性率比较,差异均有统计学意义(P<0.05)。结论:血清及癌组织VEGF及其受体在结肠癌患者中呈现异常表达,且不同分期与分化程度结肠癌患者的表达也存在一定差异,血清及癌组织VEGF及其受体表达可能与结肠癌疾病进展、临床分期和病理分化程度密切相关,在结肠癌患者中具有较高的临床检测价值。

Objective:To observe the change situation of serum and cancer tissue VEGF(VEGF-A,VEGF-C)and its receptors(VEGFR-3)of patients with colon cancer.Method:A total of 100 patients with colon cancer diagnosed and treated in our hospital from March 2013 to May 2018 were selected as observation group,and 100 patients with benign colon lesions in the same period were selected as control group.The serum levels of VEGF and its receptor,the positive rate of tissue VEGF and its receptor were detected and compared between two groups,and the differences in different stages and differentiation degree of observation group were compared.Result:The serum levels of VEGF and its receptor,the positive rates of tissue VEGF and its receptor in observation group were higher than those of control group,and the serum levels of VEGF and its receptor,the positive rates of tissue VEGF and its receptor in patients with colon cancer of different stages and differentiation degrees were compared,the differences were statistically significant(P<0.05).Conclusion:The serum and cancer tissue VEGF and its receptors of patients with colon cancer show abnormal expression,and the expression of patients with different stages and differentiation degree of colon cancer had certain differences too,the expression of serum and cancer tissue VEGF and its receptors may have close relationship to the disease rogression,clinical stage and pathological differentiation of colon cancer,so they have higher detection value for the patients with colon cancer.